COVID Treatment and Vaccine Drug Pipeline Report- July 2020 Update

COVID Treatment and Vaccine Drug Pipeline Report- July 2020 Update

  • July 2020 •
  • 170 pages •
  • Report ID: 5878754 •
  • Format: PDF
COVID-19 condition is currently one of the most researched diseases across the world and presents a robust pipeline with more than 300 companies participating in COVID treatment and COVID vaccine development.
As of July 2020, a total of 20 phase-3 stage of clinical trials, 57 candidates in Phase-2 stage, and 15 therapeutic candidates are in phase 1 stage of development. In addition, the pre-clinical phase candidates present most optimistic treatment options for COVID treatment and vaccination with 108 candidates currently under development and 127 companies in research phase.

COVID pandemic continues to impact individual health and business operations worldwide. Companies like Gilead Sciences have registered their drug candidates for the treatment of coronavirus across multiple countries.
The current edition of the COVID-19 drug and vaccine pipeline study is the eighth edition put forward by the publisher analysing coronavirus treatment and vaccine compounds and molecules under development.
Both small size and large size pharmaceutical companies are investing in drug development operations. Further, financial entities worldwide are extending support to small pharmaceutical companies, universities and other researchers for development of treatment and vaccination against novel corona virus infected COVID 19.
Details of each COVID pipeline candidate including companies involved, current status of development, licenses/collaborations, clinical trial details, new molecular entities, mechanism of action, route of administration and others.

Snapshot-

Phase 3 - Twenty companies are currently active in phase-3 COVID treatment, which include- Abivax SA, Alexion Pharmaceuticals Inc, AstraZeneca Plc, Beijing Defengrei Biotechnology, Biocad, Biohaven Pharmaceuticals Inc, Biophytis SA, CytoDyn Inc, Eli Lilly and Company, FibroGen Inc, FUJIFILM Toyama Chemical Co Ltd, Immunic Inc, Insmed Inc, NeuroActiva Inc, OncoImmune Inc, Regeneron Pharmaceuticals Inc, Romark Laboratories LC, Serum Institute of India Ltd, Swedish Orphan Biovitrum AB, Vanda Pharmaceuticals Inc

Phase 2 - 57 companies are currently developing Phase-2 COVID drug options including- AB Science, Acerta Pharma, Akari Therapeutics Plc, Aldeyra Therapeutics Inc, Amarin Corp, Ansun Biopharma Inc, Apeiron Biologics GMBH, Applied Therapeutics Inc, Ascletis Pharma Inc, AstraZeneca Plc, aTyr Pharma Inc, BerGenBio SA, BioNTech SE, Blade Therapeutics Inc, Bristol-Myers Squibb Co, Bukwang Pharm Co Ltd, CalciMedica Inc, Can-Fite BioPharma Ltd, Celularity Inc, Eiger BioPharmaceuticals Inc, Eli Lilly and Company, Genentech, GeneOne Life Science, Genexine Inc, Globavir Biosciences Inc, Grifols SA, Hope Biosciences LLC, I-MAB Biopharma Co Ltd, ImmuneMed, Immunitor Inc, Janssen Pharmaceuticals, Karyopharm Therapeutics Inc, Kinevant Sciences Ltd, Laurent Pharmaceuticals Inc, Moderna Therapeutics Inc, NeuroClear Technologies Inc, Novartis AG, Novavax Inc, Pacific Meinuoke Bio Pharmaceutical, Pfizer Inc, PharmaMar SA, Pulmotect Inc, RedHill Biopharma Ltd, Relief Therapeutics Holdings AG, resTORbio Inc, Ridgeback Biotherapeutics LP, Roche AG, Sanotize Research and Development Corp, Sinovac Biotech Ltd, Synairgen Plc, Tianjin CanSino Biotechnology Inc, Tobira Therapeutics Inc, UCB Pharma, Vicore Pharma Holding AB , Viriom Inc, Vitaeris Inc, Wuhan Institute of Biological Products Co Ltd

Phase-1 pipeline for COVID vaccines and therapeutic drugs is characterized by active presence of companies including 4D Pharma PLC, argenx SE, BioCryst Pharmaceuticals Inc, Capricor, Clover Biopharmaceuticals, Fate Therapeutics Inc, Helperby Therapeutics Group Ltd , Inovio Pharmaceuticals Inc, Izana Bioscience, Palatin Technologies Inc, Pluristem Therapeutics Inc, Regeneron Pharmaceuticals Inc, Shanghai Junshi Bioscience Co Ltd, Vaxine Pty Ltd, ychan Pte. Ltd.

Pre-clinical trials for COVID are being conducted by 4D Pharma PLC, Abnova Corporation, Acer Therapeutics Inc, Agenus Inc, AIM ImmunoTech Inc, Aldeyra Therapeutics Inc, Altimmune Inc, Aptorum Group Limited, Arcturus Therapeutics Holdings Inc , AriBio Co Ltd, Aridis Pharmaceuticals Inc, ARMS Pharmaceutical LLC, Array BioPharma Inc, AstraZeneca Plc, Atossa Therapeutics Inc, Beyond Air Inc, BeyondSpring Inc, Bharat Biotech International Ltd, BioNet- Asia Co Ltd, BioNtech SE, Celltrion Inc, Centivax, Chimeron Bio, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Cocrystal Pharma Inc, Codagenix Inc, CureVac AG, CytoAgents, Daiichi Sankyo Co Ltd, Dilafor AB, Dong Wha Pharmaceutical, Eagle Pharmaceuticals Inc, Elixirgen Therapeutics Inc, Emergent BioSolutions Inc, ENDECE LLC, Ennaid Therapeutics LLC, Ensysce Biosciences Inc, EpicentRx Inc, Epitopoietic Research Corporation, EpiVax Inc, eTheRNA Immunotherapies NV, EUCYT Laboratories LLC, FibroGenesis LLC, FirstWave Bio, Flow Pharma Inc, GeoVax Labs, GigaGen Inc, Glycovax Pharma, GRDG Sciences, Grifols SA, HaloVax LLC, Heat Biologics Inc, iBio Inc, IGY Life Sciences, IMV Inc, INTELLiSTEM Technologies Inc, Janssen Vaccines and Prevention B.V, Kazia Therapeutics Ltd, Lineage Cell Therapeutics, LineaRx Inc, Medicago Inc, MedinCell S.A., Meissa Vaccines Inc, Memgen Corp, Merck & Co, Moleculin Biotech inc, Oncogenuity Inc, Oncology Venture US, Oragenics Inc, OyaGen Inc, PDS Biotechnology Corporation, PepTC Vaccines Limited, Precision NanoSystems Inc, Primmune Therapeutics Inc, Proteostasis Therapeutics Inc, PTC Therapeutics Inc, Qualigen Therapeutics Inc, Radikal Therapeutics Inc, RedHill Biopharma Ltd, Regeneron Pharmaceuticals Inc, ReiThera Srl, Renibus Therapeutics Inc, RNAimmune Inc, SAB Biotherapeutics Inc, Sanofi pasteur, Sanofi SA, Secarna Pharmaceuticals GmbH&Co.KG, Senzer Pharmaceuticals, Shanghai Junshi Biosciences Co Ltd, SK bioscience, Sorrento Therapeutics Inc, Spring Bank Pharmaceuticals Inc, Stabilitech Biopharma Ltd, Starpharma Holdings Ltd, Stemirna Therapeutics Co Ltd, Telios Pharmaceuticals Inc, Tonix Pharmaceuticals Holding Corp, UbiVac LLC, Vaxart Inc, Vaxil Bio Ltd, VBI Vaccines Inc, Verndari Inc, Vir Biotechnology Inc, Xiamen Innovax Biotech, YUMAB Gmbh, Zhittya Genesis Medicine, Zydus Cadila

Research phase COVID drugs and vaccines are being assessed by 48Hour Discovery Inc, 7 Hills Pharma LLC, A2A Pharmaceuticals Inc, AbCellera Biologics Inc , Active Motif Inc, Adaptive Biotechnologies Inc, AdaptVac, AIkido Pharma Inc, Airway Therapeutics Inc, AJ Vaccines A/S, Akers Biosciences Inc, Akshaya Bio Inc, Aligos Therapeutics Inc, Alkido Pharma Inc, Amarillo Biosciences Inc, Anixa Biosciences Inc, Applied Biology Inc, Arbutus Biopharma Corp, Arrowhead Pharmaceuticals Inc, ARTES Biotechnology Gmbh, AstraZeneca Plc, Atreca Inc, AUM LifeTech Inc, Avacta Life Sciences Limited, Avalon GloboCare Corp, AvantGen Inc, Axon Neuroscience SE, Berlin Cures Holding AG, Biocad, Bioxytran Inc, Bold Therapeutics Inc, BriaCell Therapeutics Corp, Capricor Therapeutics Inc, CellPoint LLC, CEL-SCI Corporation, Chugai Pharmabody Research, Cobra Biologics Ltd, Codagenix Inc, Codiak BioSciences Inc, Cytovia Therapeutics Inc, Cyxone AB, Dyadic International Inc, Emergent BioSolutions Inc, Emergex vaccines Ltd, Entos Pharmaceuticals Inc, EpiVax Inc, Exscientia Ltd, Generex Biotechnology Corp, Glycovax Pharma Inc, Hemogenyx Pharmaceuticals Plc, Hetero Labs Ltd, Hoth Therapeutics Inc, IDBiologics Inc, ImmuneCyte Inc, ImmunityBio Inc, Immunomic Therapeutics Inc, ImmunoPrecise Antibodies Ltd, Imophoron Ltd, Innovation Pharmaceuticals Inc, Intravacc, Iontas Ltd, IVIEW Therapeutics Inc, Jiangsu Alphamab Biopharmaceuticals, kali-extracts Inc, Kamada Ltd, Kleo Pharmaceuticals Inc, Ligandal Inc, Mabpharm Ltd, Manhattan BioSolutions LLC, Mateon Therapeutics Inc, Memo Therapeutics AG, MigVax Ltd, Molecular Partners AG, Mymetics Corporation, NanoViricides Inc, Nascent Biotech Inc, Neovii Biotech, Neurimmune AG, NuGenerex Immuno-Oncology Inc, OliX Pharmaceuticals Inc, Ology Bioservices Inc, OncoSec Medical Inc, Orgenesis Inc, OSE Immunotherapeutics, Panacea Biotec Ltd, PeptiDream Inc, Pfizer Inc, Phylex BioSciences Inc, Phytoption LLC, Pneumagen Ltd, Predictive Oncology, Prellis Biologics Inc, Q BioMed Inc, Qurient Co Ltd, Regeneron Pharmaceuticals Inc, Resverlogix Corp, Sanofi Pasteur, Sarepta Therapeutics Inc, Scancell Holdings plc, Senhwa Biosciences, Sirnaomics Inc, Sirona Biochem Corp, SmartPharm Therapeutics Inc, Soligenix Inc, SOM Biotech, Sosei Heptares, Sunshine Biopharma Inc, Synlogic Inc, Takara Bio Inc, Takeda Pharmaceutical Company Ltd, Takis Biotech, Tetra Bio Pharma, TFF pharmaceuticals Inc, Themis Bioscience GmBH, Twist Bioscience Corp, Ufovax Inc, UMN Pharma Inc, United Biomedical Inc, Valneva SE, Valo Therapeutics Ltd, Vanda Pharmaceuticals Inc, Vaxil BioTherapeutics, Vir Biotechnology Inc, Viravaxx AG, Virna therapeutics, WuXi Biologics Inc, XORTX Therapeutics Inc

Report Scope:
• 350+ drugs and vaccines, 300+ companies covered
For each COVID-19 drug or vaccine candidate
• New molecular entities identified
• Pre-clinical, research, clinical stage products analysed
• Current status and recent developments, Mechanism of Action, Phase, companies involved, Route of Administration, New Molecular Entity